B细胞去除治疗类风湿关节炎

B cell depletion in treating rheumatoid arthritis

摘要:B细胞通过多重机制在类风湿关节炎(RA)发病中起关键作用。大量临床研究也发现,抗CD20单克隆抗体(R ituxim ab)通过选择性去除B细胞,对顽固性RA患者有很好的治疗作用,且有较好的安全性。美国食物药品管理局(FDA)已批准对于中-重度RA,如对一种或以上TNF-α生物制剂疗效不佳,可使用R ituxim ab治疗。

B cells play a central role in the pathogenesis of rheumatoid arthritis （RA） through multiple mechanisms. Clinical trials have demonstrated that anti-CD20 monoelonal antibody（Rituximab） is effective and safe to treat refractory RA through depletion of B cells. Rituximab is now approved by FDA for use concurrently with methotrexate to treat RA in patients who have an inadequate response to one or more tumor necrosis factor inhibitors.